RHU CONDOR reposted this
Last week, we were thrilled to join the 2nd Symposium on Microenvironment and #Immunotherapy of Sarcomas, hosted by RHU CONDOR, which took place last week in Bordeaux, France. This symposium is a vital platform for advancing our understanding of soft tissue sarcomas (STS) and exploring innovative treatment strategies that address specific challenges faced by patients. Why is this important? STS are rare and often diagnosed late. Despite well-conducted surgeries, up to 40% of patients develop metastatic relapse, with standard treatments offering limited effectiveness. But there’s hope! The RHU CONDOR, led by Prof. Italiano Antoine, an esteemed member of Domain's Scientific Advisory Board (SAB), aims to revolutionize treatment options for STS patients by combining #precisionmedicine and immunotherapies. As proud members of this groundbreaking program, we're dedicated to pioneering innovations in GPCR-targeting immunotherapies. Our lead clinical candidate, DT-9081, an EP4R antagonist, is set to enter Phase II in early 2025. DT-9081 has the potential to improve immune responses to sarcoma and address resistance mechanisms to current therapies, offering greater benefits to patients. We had the pleasure of attending insightful presentations by Florent Petitprez The University of Edinburgh Prof. Wolf Hervé Fridman Université Paris Cité Dr. Sandra D'Angelo Memorial Sloan Kettering Cancer Center Dr. Ryan Denu MD Anderson Cancer Center. Additionally, Prof. John Stagg, another distinguished member of Domain's SAB, discussed targeting GPCRs in solid tumors, highlighting the role of PAR2 in cancer immunity. Dr. Thibaut Brugat, our Head of Portfolio, also gave an engaging presentation on therapeutic target identification and selection of a drug candidate with a superior mode of action. Together, we're paving the way for more effective and safer treatments for sarcoma patients. Stay tuned for more updates on our journey to innovate and drive meaningful change for those affected by this challenging disease! #Healthinnovation #cancerresearch #drugdevelopment
